CG-806 is a small molecule inhibitor primarily designed for the treatment of various cancers, particularly those associated with mutations in the FLT3 and BTK genes. It is classified as a selective inhibitor, which means it targets specific proteins involved in cancer cell proliferation and survival, thereby potentially reducing side effects compared to non-selective treatments. CG-806 has shown promise in preclinical studies for its ability to induce apoptosis in cancer cells and inhibit tumor growth. Its mechanism of action involves the disruption of signaling pathways that are critical for the survival of malignant cells. Additionally, CG-806 is notable for its oral bioavailability, which facilitates patient compliance in clinical settings. The compound is currently under investigation in clinical trials to evaluate its efficacy and safety in humans. As with many investigational drugs, ongoing research aims to better understand its pharmacokinetics, optimal dosing regimens, and potential resistance mechanisms that may arise during treatment.

CG-806

1370466-81-1: CG-806 is a small molecule inhibitor primarily designed for the treatment of various cancers, particularly those associated with mutations in the FLT3 and BTK genes. It is classified as a selective inhibitor, which means it targets specific proteins involved in cancer cell proliferation and survival, thereby potentially reducing side effects compared to non-selective treatments. CG-806 has shown promise in preclinical studies for its ability to induce apoptosis in cancer cells and inhibit tumor growth. Its mechanism of action involves the disruption of signaling pathways that are critical for the survival of malignant cells. Additionally, CG-806 is notable for its oral bioavailability, which facilitates patient compliance in clinical settings. The compound is currently under investigation in clinical trials to evaluate its efficacy and safety in humans. As with many investigational drugs, ongoing research aims to better understand its pharmacokinetics, optimal dosing regimens, and potential resistance mechanisms that may arise during treatment.

N-[4-[2,3-Dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl]-3-fluorophenyl]-N'-[3-(trifluoromethyl)phenyl]-urea

<p>BTK-IN-24 is a Bruton's tyrosine kinase (BTK) inhibitor with potential anticancer activity, and it can be used in the study of myeloproliferative disorders.</p>

CAS 1370466-81-1

CG-806

N-[4-[2,3-Dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl]-3-fluorophenyl]-N'-[3-(trifluoromethyl)phenyl]-urea

Ref: TR-D118130

BTK-IN-24

Ref: TM-T14937